219 related articles for article (PubMed ID: 34327136)
1. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
Han C; Ye S; Hu C; Shen L; Qin Q; Bai Y; Yang S; Bai C; Zang A; Jiao S; Bai L
Front Oncol; 2021; 11():684867. PubMed ID: 34327136
[TBL] [Abstract][Full Text] [Related]
2. Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study.
Chen Y; Hong H; Fang W; Zhang X; Luo H; Chen Z; Yu J; Fan W; Chi X; Peng Y
Front Oncol; 2023; 13():1113389. PubMed ID: 37007075
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study.
Zhang CS; Zeng ZM; Zhuo MY; Luo JR; Zhuang XH; Xu JN; Zeng J; Ma J; Lin HF
Oncologist; 2023 Dec; 28(12):e1239-e1247. PubMed ID: 37329569
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204).
Zheng Y; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Xu N
Cancer; 2024 Jun; 130(12):2180-2190. PubMed ID: 38412283
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Qiao Q; Han C; Ye S; Li J; Shao G; Bai Y; Xu A; Sun M; Wang W; Wu J; Huang M; Song L; Huang L; Liu T; Liu W; Wang ZM; Li B; Xia M; Bai L
Front Immunol; 2023; 14():1238667. PubMed ID: 37942328
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
[TBL] [Abstract][Full Text] [Related]
9. Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201).
Song Y; Zhou K; Jin C; Qian Z; Hou M; Fan L; Li F; Ding K; Zhou H; Li X; Chen B; Sun X; Song X; Jiang M; Zhang Q; Liu L; Yu G; Hu Y; Zhao Z; Liu L; Xue H; Luo J; He B; Jin X; Zhao M; Li B; Xia Y; Zhu J
Front Oncol; 2022; 12():925236. PubMed ID: 35875118
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
Front Immunol; 2022; 13():944062. PubMed ID: 36091003
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.
Chen X; Li W; Wu X; Zhao F; Wang D; Wu H; Gu Y; Li X; Qian X; Hu J; Li C; Xia Y; Rao J; Dai X; Shao Q; Tang J; Li X; Shu Y
Front Oncol; 2022; 12():909035. PubMed ID: 35712486
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study).
Chen Y; Zhang J; Han G; Tang J; Guo F; Li W; Xie L; Xu H; Zhang X; Tian Y; Pan L; Shu Y; Ma L; Chen X
Front Immunol; 2023; 14():1232858. PubMed ID: 38022553
[TBL] [Abstract][Full Text] [Related]
13. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
Huang Z; Pang X; Zhong T; Qu T; Chen N; Ma S; He X; Xia D; Wang M; Xia M; Li B
Front Immunol; 2022; 13():924542. PubMed ID: 35833116
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report.
Zhang Z; Li Y; Dong Y; Li J; Zhang B; Zhang C; Cui X
Front Oncol; 2022; 12():846597. PubMed ID: 35321433
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.
Zhu J; Song C; Zheng Z; Xia L; Chen Y; Ke G; Wu X
Front Oncol; 2021; 11():720343. PubMed ID: 34796105
[TBL] [Abstract][Full Text] [Related]
17. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
Zheng Y; Mislang ARA; Coward J; Cosman R; Cooper A; Underhill C; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Jin X; Li B; Wang ZM; Kwek KY; Xia D; Xia Y; Xu N
Cancer Immunol Immunother; 2022 Oct; 71(10):2371-2379. PubMed ID: 35165764
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
Xu B; Pan Q; Pan H; Li H; Li X; Chen J; Pang D; Zhang B; Weng D; Peng R; Fang M; Zhang X
EClinicalMedicine; 2023 Oct; 64():102240. PubMed ID: 37767191
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
